Logo

Tekmira Acquires License to Novel RNAi Technology for Therapeutic Development

Aug 25, 2011
Premium

Tekmira Pharmaceuticals said this week that it has acquired an exclusive, worldwide license to an RNAi technology developed by Halo-Bio RNAi Therapeutics.

The technology, called multivalent RNAi, comprises “single macromolecules capable of mediating RNAi at multiple unique target sites,” Tekmira said. “MV-RNA can target three sites on a single gene or up to three separate genes simultaneously.”

Tekmira said that it aims to combine the molecules with its proprietary lipid nanoparticles to develop therapeutics.

Financial terms of the arrangement were not disclosed.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Business News
licensing agreement
RNAi
Tekmira
Breaking News
The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.